但中位总生存期，次要观察终点，联合组为20.5个月，而单药治疗组为20.6个月。
But median overall survival, a secondary end point, was 20.5 months in the combination group and 20.6 months in the monotherapy group.
研究人员提到，在两组中总生存期和无进展生存也没有差异。
Overall survival and progression-free survival also did not differ in the two groups, the researchers note.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
两治疗组的无进展生存期和总生存期都没有明显的差异。
Neither progression-free survival nor overall survival differed significantly between the treatment arms.
应用推荐